Last reviewed · How we verify

TERIPARATIDE — Competitive Intelligence Brief

TERIPARATIDE (TERIPARATIDE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Parathyroid Hormone Analog [EPC].

marketed Parathyroid Hormone Analog [EPC] Recombinant protein Live · refreshed every 30 min

Target snapshot

TERIPARATIDE (TERIPARATIDE).

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TERIPARATIDE TARGET TERIPARATIDE marketed Parathyroid Hormone Analog [EPC] 2002-01-01
Teriparatide (Forteo) Teriparatide (Forteo) M.D. Anderson Cancer Center marketed Parathyroid hormone analog PTH1 receptor (parathyroid hormone 1 receptor)
Teriparatide (rDNA origin) Teriparatide (rDNA origin) Bio Sidus SA marketed Parathyroid hormone analog PTH1 receptor (PTHR1)
FORSTEO FORSTEO Shenzhen Salubris Pharmaceuticals Co., Ltd. marketed Parathyroid hormone analog PTH1 receptor
Teriparatide Pen Injector Teriparatide Pen Injector University of Edinburgh marketed Parathyroid hormone analog PTH1 receptor
Teriparatide (PF708) Teriparatide (PF708) Pfenex, Inc phase 3 Parathyroid hormone analog PTH1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Parathyroid Hormone Analog [EPC] class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TERIPARATIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/teriparatide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: